{"DataElement":{"publicId":"7620995","version":"1","preferredName":"First Antibacterial Agent Administered Type","preferredDefinition":"A description of the first antibacterial agent that was administered.","longName":"7620994v1.0:5073152v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7620994","version":"1","preferredName":"First Antibacterial Agent Administered","preferredDefinition":"Preceding all others in time or space or degree._A family of substances capable of destroying or inhibiting the growth of bacteria._The act of having given something (e.g., a medication or test).","longName":"5084111v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5084111","version":"1","preferredName":"First Antibacterial Agent","preferredDefinition":"Preceding all others in time or space or degree.:A family of substances capable of destroying or inhibiting the growth of bacteria.","longName":"C25509:C52588","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibacterial Agent","conceptCode":"C52588","definition":"A family of substances capable of destroying or inhibiting the growth of bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26A3F73B-7610-A576-E050-BB89AD431B74","latestVersionIndicator":"Yes","beginDate":"2015-12-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-11","modifiedBy":"ONEDATA","dateModified":"2015-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE888A2-7374-7A9B-E053-4EBD850ADDE1","latestVersionIndicator":"Yes","beginDate":"2021-04-01","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-01","modifiedBy":"MALUMK","dateModified":"2021-07-27","changeDescription":"Released 07/27/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5073152","version":"1","preferredName":"Antibacterial Agent Type","preferredDefinition":"A family of substances capable of destroying or inhibiting the growth of bacteria._Something distinguishable as an identifiable class based on common qualities.","longName":"5073152v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Levofloxacin IV or oral","valueDescription":"Intravenous Route of Administration Or Oral Route of Administration Levofloxacin","ValueMeaning":{"publicId":"5073159","version":"1","preferredName":"Intravenous Route of Administration Or Oral Route of Administration Levofloxacin","longName":"5073159","preferredDefinition":"Administration within or into a vein or veins.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.: A broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Levofloxacin","conceptCode":"C1586","definition":"A broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2618D248-4734-E9FA-E050-BB89AD430D92","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2618D248-474D-E9FA-E050-BB89AD430D92","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Cefpodoxime oral","valueDescription":"Oral Route of Administration Cefpodoxime","ValueMeaning":{"publicId":"5073160","version":"1","preferredName":"Oral Route of Administration Cefpodoxime","longName":"5073160","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.: A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cefpodoxime","conceptCode":"C65305","definition":"A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2618D248-475B-E9FA-E050-BB89AD430D92","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2618D248-4774-E9FA-E050-BB89AD430D92","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Moxifloxacin IV or oral","valueDescription":"Intravenous Route of Administration Or Oral Route of Administration Moxifloxacin","ValueMeaning":{"publicId":"5073158","version":"1","preferredName":"Intravenous Route of Administration Or Oral Route of Administration Moxifloxacin","longName":"5073158","preferredDefinition":"Administration within or into a vein or veins.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.: A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Moxifloxacin","conceptCode":"C62052","definition":"A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2618D248-470C-E9FA-E050-BB89AD430D92","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2618D248-4725-E9FA-E050-BB89AD430D92","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Cefdinir oral","valueDescription":"Oral Route of Administration Cefdinir","ValueMeaning":{"publicId":"5073161","version":"1","preferredName":"Oral Route of Administration Cefdinir","longName":"5073161","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.: A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefdinir's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefdinir inhibits bacterial septum and cell wall synthesis formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cefdinir","conceptCode":"C28914","definition":"A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefdinir's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefdinir inhibits bacterial septum and cell wall synthesis formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2618D248-4781-E9FA-E050-BB89AD430D92","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2618D248-479A-E9FA-E050-BB89AD430D92","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Other antibacterial drug","valueDescription":"Other Antibacterial Agent","ValueMeaning":{"publicId":"5073162","version":"1","preferredName":"Other Antibacterial Agent","longName":"5073162","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A family of substances capable of destroying or inhibiting the growth of bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibacterial Agent","conceptCode":"C52588","definition":"A family of substances capable of destroying or inhibiting the growth of bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2618D248-47A8-E9FA-E050-BB89AD430D92","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2618D248-47C1-E9FA-E050-BB89AD430D92","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Vancomycin IV","valueDescription":"Intravenous Route of Administration Vancomycin","ValueMeaning":{"publicId":"5073163","version":"1","preferredName":"Intravenous Route of Administration Vancomycin","longName":"5073163","preferredDefinition":"Administration within or into a vein or veins.: A branched tricyclic glycosylated peptide with bactericidal activity against most organisms and bacteriostatic effect on enterococci. At a site different from that of penicillins and cephalosporins, vancomycin binds tightly to the D-alanyl-D-alanine portion of cell wall precursors, thereby interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins that destroy the cell wall by lysis. Vancomycin may also alter the permeability of bacterial cytoplasmic membranes and may selectively inhibit RNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vancomycin","conceptCode":"C925","definition":"A branched tricyclic glycosylated peptide with bactericidal activity against most organisms and bacteriostatic effect on enterococci. At a site different from that of penicillins and cephalosporins, vancomycin binds tightly to the D-alanyl-D-alanine portion of cell wall precursors, thereby interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins that destroy the cell wall by lysis. Vancomycin may also alter the permeability of bacterial cytoplasmic membranes and may selectively inhibit RNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2618D248-47CE-E9FA-E050-BB89AD430D92","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2618D248-47E7-E9FA-E050-BB89AD430D92","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Amoxicillin clavulanate oral","valueDescription":"Oral Route of Administration Amoxicillin-Clavulanate Potassium","ValueMeaning":{"publicId":"5073164","version":"1","preferredName":"Oral Route of Administration Amoxicillin-Clavulanate Potassium","longName":"5073164","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.: A combination of the semisynthetic broad-spectrum antibiotic amoxicillin and the beta-lactamase enzyme inhibitor clavulanate potassium. Clavulanate potassium increases the serum half-life of amoxicillin by inhibiting beta-lactamase-mediated metabolism of amoxicillin.  Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell walls.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Amoxicillin-Clavulanate Potassium","conceptCode":"C1023","definition":"A combination of the semisynthetic broad-spectrum antibiotic amoxicillin and the beta-lactamase enzyme inhibitor clavulanate potassium. Clavulanate potassium increases the serum half-life of amoxicillin by inhibiting beta-lactamase-mediated metabolism of amoxicillin.  Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell walls.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2618D248-47F4-E9FA-E050-BB89AD430D92","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2618D248-480D-E9FA-E050-BB89AD430D92","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Ciprofloxacin IV or oral","valueDescription":"Intravenous Route of Administration Or Oral Route of Administration Ciprofloxacin","ValueMeaning":{"publicId":"5073153","version":"1","preferredName":"Intravenous Route of Administration Or Oral Route of Administration Ciprofloxacin","longName":"5073153","preferredDefinition":"Administration within or into a vein or veins.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.: A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ciprofloxacin","conceptCode":"C375","definition":"A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2617DC93-8CF8-9DF5-E050-BB89AD434BBD","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2617DC93-8D11-9DF5-E050-BB89AD434BBD","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Ertapenem IV","valueDescription":"Intravenous Route of Administration Ertapenem","ValueMeaning":{"publicId":"5118236","version":"1","preferredName":"Intravenous Route of Administration Ertapenem","longName":"5118236","preferredDefinition":"Administration within or into a vein or veins.: A 1-beta-methyl carbapenem and broad-spectrum beta-lactam antibiotic with bactericidal property. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and subsequent lysis of the cell wall leading to cell death of Gram-positive and Gram-negative aerobic and anaerobic pathogens. This agent is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ertapenem","conceptCode":"C61752","definition":"A 1-beta-methyl carbapenem and broad-spectrum beta-lactam antibiotic with bactericidal property. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and subsequent lysis of the cell wall leading to cell death of Gram-positive and Gram-negative aerobic and anaerobic pathogens. This agent is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AD0A21F-DC19-05F3-E050-BB89AD436DB8","latestVersionIndicator":"Yes","beginDate":"2016-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2AD0A21F-DC32-05F3-E050-BB89AD436DB8","beginDate":"2016-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-02","modifiedBy":"ONEDATA","dateModified":"2016-02-02","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"4001711","version":"1","preferredName":"None","longName":"4001711","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED6DCE6B-B411-EF30-E040-BB89AD4369A8","latestVersionIndicator":"Yes","beginDate":"2013-12-13","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-12-13","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE625A50-E17B-2115-E053-4EBD850A9034","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"},{"value":"Penicillin","valueDescription":"Penicillin Antibiotic","ValueMeaning":{"publicId":"2624960","version":"1","preferredName":"Penicillin Antibiotic","longName":"2624960","preferredDefinition":"An antibiotic drug used to treat infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penicillin Antibiotic","conceptCode":"C1500","definition":"Any beta-lactam antibiotic derived from Penicillium fungi with bactericidal activity. Penicillin antibiotics bind to and inactivate penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FB55C-F40C-122E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE625A50-E185-2115-E053-4EBD850A9034","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"ONEDATA","dateModified":"2021-03-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5073151","version":"1","preferredName":"Antibacterial Agent Type","preferredDefinition":"A family of substances capable of destroying or inhibiting the growth of bacteria.:Something distinguishable as an identifiable class based on common qualities.","longName":"C52588:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibacterial Agent","conceptCode":"C52588","definition":"A family of substances capable of destroying or inhibiting the growth of bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2617DC93-8CCC-9DF5-E050-BB89AD434BBD","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2617DC93-8CDD-9DF5-E050-BB89AD434BBD","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"MALUMK","dateModified":"2021-03-25","changeDescription":".PVs added for 2100r7. 03/25/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"HPST_IP_frst_antibac_agt_typ","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the first antibacter","type":"Preferred Question Text","description":"What was the first antibacterial agent that was administered?","url":null,"context":"NHLBI"},{"name":"Specify the first antibacterial drug given","type":"Application Standard Question Text","description":"Specify the first antibacterial drug given","url":null,"context":"NHLBI"},{"name":"Specify the first antibacterial drug given","type":"Alternate Question Text","description":"Specify the first antibacterial drug given","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Alternate Question Text","description":"Specify the first antibacterial drug given as prophylaxis","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE9B965-4898-6C68-E053-4EBD850A4102","latestVersionIndicator":"Yes","beginDate":"2021-04-01","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-01","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":"Released. 07/27/2021 KMM; System generated def displayed as alt def. ALT name added for 2100r7. 10/04/2021 KMM","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002666. ak","unresolvedIssues":null,"deletedIndicator":"No"}}